NOVEL POLYPEPTIDES AND THEIR USE

Abstract: A polypeptide comprising the following amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Ph e-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro- Pro-Arg-Phe-Pro; and functional derivatives thereof; pharmaceutical compositions containing such polypeptides; and a method of inhibiting bacterial growth.

Description: Novel polvpeotides and their use. The present invention relates to new polypeptides ha¬ ving bacteriocidal activity in that they are capable of kil¬ ling certain bacteria, particularly gram-negative ones. The invention also covers pharmaceutical compositions and methods of use for the inhibition of bacterial growth. The small intestine is an important endocrine organ and a number of physiologically active peptides have been initially isolated from porcine tissue (Mutt, V., Chemica Scripta 26B, 191-207 (1986>). During normal healthy condi¬ tions, the upper part of the small intestine contains few bacteria. Below the duodenum the concentration of bacteria progressively increases until the maximum, 10* bacteria per g of feces, is reached in the large intestine. It is remark- able that such a mass of bacteria can coexist with a delicate host organ. Small basic peptides called cecropins play an important role in insect immunity (Boman, H.G. & Hultmark, D., D.Ann.Rev.Microbiol . 41, 103-126 (1987)) and structurally unrelated peptides called magainins (Zasloff, M. , Proc.Natl. Acad.Sci. USA, 84, 5449-5453 (1987)) protect the frog skin from infections. Another group of antibacterial peptides, the defensins were first isolated from mammalian granulocytes (Selstedt, M.E., Szklarek, D. & Lehrer, R.I. Infect . Im un . 45, 150-154 (1984)) and neutrop ils (Selstedt, M.E., Brown, D.M., DeLange, R.J., Harwig, S.S. & Lehrer, R.I., J.Biol. Che . 260, 4579-4584 (1985)) and recently also from insects (Matsuyama, . & Natori, S. J.Biol.Chem. 263, 17112-17116 (1988); Lambert, J. et al. Proc .Natl .Acad . Sci . USA 86, 262- -266 (1989)). In addition, bovine neutrophils have been found to contain bactenecinβ (Romeo, D., Skerlavaj, B., Bologneεi, M & Gennaro, R. J.Biol.Chem. 263, 9573-9575 (1988), another small basic peptide. Both defensins and the small bactenecin contain one or more disulfide bridges while cecropins and magainins are cysteine-free . Frank et al (J. Biol . Chem. 255:18871-18874) have described two large bactenicins with high contents of proline and arginine and without cysteine. The present invention has for an object to provide new bactericidal polypeptides capable of inhibiting bacterial growth, in particular the growth of gram negative bacteria. In this disclosure the term "inhibiting" also includes the killing of bacteria. Another object of the invention is to provide composi¬ tions containing as an active constituent such polypeptides. Yet another object of the invention is to provide a method of treatment directed to inhibition of bacterial growth in animals, in particular mammals including man. For these and other objects wich will be clear from the following disclosure the invention provides a polypeptide having the amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg- Pro-Pro-Pro-Phe-Phe-Pro-Fro-Arg-Leu-Pτo-Pro-Arg-Ile-Pro-Pro- -Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro, and the invention also includes functional derivatives such as a few conservative amino acid replacements and the C-terminal amide. The polypeptide of the present invention and its func- tional derivatives are all therapeutically useful, particu¬ larly as antibacterial agents. Thus, they are capable of in¬ hibiting growth of bacteria or killing bacteria, in particu¬ lar gram-negative bacteria making them useful for different therapeutic purposes. This will be further illustrated by specific examples which are given below. The active polypeptide according to the present inven¬ tion can be formulated for use in human or veterinary medici¬ ne for therapeutic or profylactic use. The active prepara¬ tions are normally administered orally, rectally or parente- rally, such as by injection in the form of a pharmaceutical preparation or composition comprising the active constituents in combination with a pharmaceutically acceptable carrier which may be solid, semi-solid or liquid, or contained in a capsule, such as when orally administrered. The administra- tion may also take the form of topical application. As examp¬ les of pharmaceutical preparations there may be mentioned tablets, drops, solutions and suppositories. Usually, the active constituent constitutes the minor part of the prepara¬ tion, such as from about 0.1 to about 50% thereof based on weight . In order to prepare pharmaceutical compositions in the form of dose units for oral application the polypeptide of the invention can be mixed with a solid, pulverulent or other carrier, for example lactose, saccharose, sorbitol, mannitol, starch, such as potatoe starch, corn starch, illopectine, cellulose derivative or gelatine, and may also include lubri¬ cants, such as magnesium or calcium stearate, or polyethylene glycol waxes compressed to the formation of tablets or bodies for dragees. The dose units may also be presented in a coated form of enteric type. By using several layers of the carrier or diluent tab¬ lets operating with slow release can be prepared. Liquid preparations for oral application or for injec¬ tion can be made in the form of elexirs, syrups or suspen¬ sions, for example solutions containing from 0.1 to 20 * by weight of active substance, sugar and a mixture of ethanol, water, glycerol, propyleneglycol and possibly other additives of a conventional nature. The dose by which the active constituent is administe¬ red may vary within wide limits and is dependent on different factors, such as the seriousness of the disorder, the age and the weight of the patient and can be adjusted individually. The invention also covers a method for therapeutic treatment of animals, such as mammals including man, said method comprising the step of administering a polypeptide as described above or a functional derivative thereof in an a- mount capable of killing bacteria or inhibiting bacterial growth in said animal. The present invention will now be further exemplified by specific examples which, however, are not to be construed as limiting the scope of the invention otherwise than accor¬ ding to the appended claims. SUBSTBTUTE SHEET EXAMPLE 1 Preparation of a oeptide concentrate A concentrate of thermostable intestinal peptides was prepared from pig small intestine essentially as described elsewhere (Mutt, V. Arkiv e i JL5., 69-74 (1959); Mutt, V. in Gut Hormones (ed. Bloom, . S.R. ) , pp 21-27, (Churchill Living¬ stone, Edinburg, 1978). Briefly, the uppermost meter of the intestine was im- mersed for 8 ± 1 in into boiling water and then cooled on ice and frozen. The frozen material was minced and extracted at 0-15°C with 0.5 M acetic acid for 12 h and the mixture filtered with suction (with the aid of "Hyflo Super-Cel", 30 g per liter suspension) . Peptides were adsorbed from the fil- trate to alginic acid and the alginic acid carrying the pep¬ tides was washed in turn with 0.005 M HCl, 95% ethanol (to remove fats) and 0.005 M HCl again. The peptides were eluted with 0.2 M ice-cold HCl and the pH of the eluate was brought to 3.5 ± 0.1 with sodium acetate. Peptides were then precipi- tated by saturating the eluate with NaCl, and the precipitate was collected by suction filtration. The amount by weight of the precipitate (wet weight) is about one thousandth of that of the boiled intestinal tissue. The concentrate was dissolved at room temperature to a 10% w/v solution in water. Two volumes of 95% ethanol were added to the solution and the (apparent) pH (as measured with a glass electrode) of it was brought to 7.5 ± 0.1 with NaOH (1M NaOH:EtOH 1:2). A precipitate formed and was removed by filtration. To the clear solution one volume of 95% ethanol precooled to -20°C was added and the suspension was kept at this temperature for 24 h whereupon it was filtered. The pep¬ tides were recovered from the filtrate in aqueous solution and precipitated at pH 3.5 ± 0.1 by saturation of the solu¬ tion with NaCl. The precipitate, collected by suction filtra- tion, weighed about 10% of that of the concentrate taken for its preparation. It was dissolved in 0.2 M AcOH and chromato- graphed in this solvent on Sephadex G-25 fine. The second half by volume of the peptidecontaining eluate from this chromatography was saturated with NaCl and the precipitate collected by suction filtration. Its weight was about 40% of that of the peptide precipitate taken for this chromatogra¬ phy. It was dissolved in water, the pH of the solution was adjusted to 4 ± 0.1 whereupon the peptides were reprecipita- ted with NaCl and the precipitate collected by suction (there was no significant difference in weight of the material befo- re and after reprecipitation) . The reprecipitated material was extracted with methanol (50 ml/g) and the MeOH-insoluble fraction was collected by suction filtration and washed on the filter with ether. The ether was evaporated in vacuo. The weight of the dry material was about 15% of "that of the pep- tide precipitate taken for extraction with MeOH. EXAMPLE 2 Purification of concentrate As a starting material for the purification there was used the concentrate resulting from Example 1. The concentra¬ te (1,5 g) was dissolved in 80 ml ammonium formate, pH 6.4, and treated with 30 ml of DEAE Sepharoβe, batch-wise. Step 1: Chromatoσraphv on CM-Sepharose CL-6B (56 ml column, equilibrated with 0.1 M ammonium formate, pH 6.4). Elution was initially carried out with 0.1 M ammonium formate (about 2100 ml) to a low extinction and then gradient elution was performed using 0.1-0.85 M ammonium acetate, pH 5.2 (300 + 300 ml). The activity leaves as an integral peak having a maximum at 0.38 M, specific activity 30-40 units/μg. (1 unit is defined as the activity of lng of cecropin A.) The frac¬ tion showing the highest antibacterial activity was chosen for further purification. Step 2: Further purification of pSCMC fraction P5CMC fraction was dissolved in 8 mg/ml H2O. 50μl of. sample (0.4 mg) was mixed with 450 μl 0.1% TFA in water and applied on a FPLC coupled Pep RPC HR5/5 (Pharmacia). The column was washed with 0.1% TFA in H2O for 10 min. at a flow rate of 0.5 ml/min. Then the acetonitrile concentration was raised to 27% in 5 min. The active material was eluted with a gradient of 27%-32% acetonitrile in 34 min. An aliquot (50 μl or 100 μl) of each fraction was dried in the Speedvac and dissolved in lOμl H2O and 3 μl was used in an antibacterial assay. Result: The active material was eluted at 28.5% acetonitrile under the chosen gradient profile. On the appended drawing there is shown a diagram on antibacterial activity (E. coli) as a function of elution time. As a test sample there was used 0.4 mg of the purified active fraction in 50 μl H2O mixed with 450 μl of 0.1% TFA in H2O. The sample was applied to Pep RPC HR5/5 coupled to FPLC. The elution program was as ollows: * Time % " acetonitrile 0 0 10 0 15 27- 49 32 54 65 EXAMPLE 3 Antibacterial assay The antibacterial activity of the polypeptide of this invention was determined by inhibition zone assay as descri¬ bed by Hult ark et al . (Hultmark, D., Engstrbm, A., Anderson, K. , Steiner, H., Bennich, H. and Boman, H.G. (1983). Insect immunity. Attacins, a family of antibacterial proteins from Hvaloohora cecropia. EMBO J. 2, 571-576). Log-phase bacteria were grown to a density of 100 units on a lett-summerson photoelectric colorimeter. They were diluted 50 times with LB medium and 50 μl of the bacte¬ ria suspension was mixed with 6 ml of 1.0% agarose in LB me- diu (w/v) and poured on the petri dishes (Falcon 1001 Opti- lux) with inner diameter 8.65 cm. For E. coli this procedure will give about 2x10^ bacteria per plate. The plates were left for 1 hour at room temperature, and holes with 3 mm diameter were made on the solidified aga- rose. 100 μl of fractions were dried in a speedvac and dis¬ solved in 10 μl H2O, of which 3 μl was applied to the holes. After 30 min diffusion time the plates were incubated at 30°C overnight. The diameter of the inhibition zones were measured and the relative unit activity was calculated from a standard curve which was constructed on varying amount of Cecropin A versus activity. One microgram of Cecropin A corresponds to 1000 units of activity. The anti-E.coli activity of PS CMC fractions Fraction No. Specific activity (units/uα) PS CMC Fr. I 0.5 PS CMC Fr. II 0.7 PS CMC Fr. Ill 1.4 PS CMC Fr. IV 2.0 PS CMC Fr. V 14.0 PS CMC Fr. VI 84.0 PS CMC Fr. VII 100.0 The anti-E.coli activity of fractions collected from the re¬ verse phase chromatoσraphy of PS CMC Fr. VII on a FPLC CQUP- Unit activity/fraction activity not detectable 8400 28000 28000 13000 7300 3500 1100 activity not detectable In this test 400 μg PS CMC Fr. VII was applied to the colu n. EXAMPLE 4 Example 3 was repeated by using Bacillus meqaterium for measuring the antibacterial activity of the present poly¬ peptide. The experiment has shown that Bacillus meoaterium is more sensitive than E.coli to the peptide, the average acti¬ vity of the polypeptide being about 3 times higher than in relation to E.coli. EXAMPLE 5 The maximum concentration of PR-peptide was 2,5 mM and 3μl was applied to each well in thin agarose plates seeded with test bacterium. LV values are obtained from a dilution serie and is the lowest concentration giving killing (Hultmark, D., Engstrbm, A., Anderson, K., Steiner, H., Bennich, H. and Bo an, H.G. (1983))

Claims: CLAIMS 1. A polypeptide .comprising the following amino acid sequence: _ Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg- Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro- -Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro. and functional derivatives thereof. 2. Polypeptide according to claim 1, in an underiva- tized form. 3. Polypeptide according to claim 1 or 2 for therapeu¬ tic use. 4. Polypeptide according to claim 3 for use as an an¬ tibacterial agent. 5. A pharmaceutical composition containing as an acti- ve constituent of the polypeptide according to claim 1 or 2 in an antibacterially effective amount together with a phar¬ maceutically acceptable carrier or diluent. 6. A pharmaceutical composition according to claim 5, wherein said carrier or diluent is acceptable for oral, in- tra uscular, intravenous or subcutaneous administration. 7 * . A method for inhibiting bacterial growth in ani¬ mals, such as mammals including man, comprising the step of administering a polypeptide according to claim 1 or 2 or a composition according to claim 5 or 6 in an inhibitory amount. 8. A method according to claim 7 for intestinal use comprising oral administration of a composition according to claim 5 or 6 in a slow release dose form. 9. A method according to claim 7, comprising admini- stration by injection of a composition according to claim 5 or 6 in an injectable dose form.

Inventors: BOMAN HANS G, JOERNVALL HANS, LEE JONG-YOUN, MUTT VIKTOR, BOMAN, HANS, G., JOERNVALL, HANS, LEE, JONG-YOUN, MUTT, VIKTOR
Applicants: BOMAN HANS G, JOERNVALL HANS, LEE JONG YOUN, MUTT VIKTOR, BOMAN, HANS, G., JOERNVALL, HANS, LEE, JONG-YOUN, MUTT, VIKTOR
Application year: 1992
Main classification: C07K13
IPC codes: A61K38, A61P31, C07K14